Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care
The treatment paradigm for metastatic castrate-sensitive prostate cancer (mCSPC) has evolved rapidly in the past decade with the approval of several life-prolonging therapies including docetaxel chemotherapy and multiple androgen receptor pathway inhibitors (ARPI) in combination with androgen depriv...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI AG
2023-04-01
|
| Serija: | Current Oncology |
| Teme: | |
| Online pristup: | https://www.mdpi.com/1718-7729/30/4/332 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|